Document:

EX-10.68.3

 Exhibit 10.68.3 

Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. 

THIRD AMENDMENT 
 TO 
 RIFAXIMIN 

MANUFACTURING AND SUPPLY AGREEMENT 
 between 
 SALIX PHARMACEUTICALS, INC. 

and 

LUPIN LTD. 

Dated as of 15 May 2013 

 This THIRD AMENDMENT TO RIFAXIMIN MANUFACTURING AND SUPPLY AGREEMENT
(this “Amendment”), dated as of 15 May 2013 (the “Third Amendment Effective Date”), is made by and between Salix Pharmaceuticals, Inc., a California corporation (“Salix”), and Lupin Ltd., a
corporation organized under the laws of India (“Lupin”). Salix and Lupin are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 

RECITALS 
 WHEREAS, the Parties are parties to that certain Rifaximin Manufacturing and Supply Agreement, dated 30 September 2009, as amended by the First Amendment thereto, dated 31 March 2011, and
the Second Amendment thereto, dated 22 February 2013 (as so amended, the “Original Agreement”); and 
 WHEREAS, the Parties wish to amend the Original Agreement as set forth herein; 
 NOW, THEREFORE, in consideration of the foregoing premises, the mutual promises and covenants of the Parties contained herein, and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 
 ARTICLE I.
DEFINITIONS 
 Terms used herein and not otherwise defined are used herein with the same meanings given to
them in the Original Agreement. 
 ARTICLE II. AMENDMENT 

The Original Agreement is hereby amended, effective as of the Third Amendment Effective Date, as follows: 

2.1     Article I of the Original Agreement is hereby amended to add the following additional
sections at the end thereof: 
 1.79     “Alfa” means Alfa Wassermann
S.p.A., an Italian company. 
 1.80     “Alfa Confidential Information” has
the meaning set forth in Section 5.8(b). 
 1.81     “Knowledge” means
the good faith understanding of any vice president, any senior vice president, or the president or chief executive officer of a Party of the facts and information then in such individual’s possession after due inquiry. 

 1.82     “Patents” means (a) all
national, regional and international patents and patent applications, including provisional patent applications, (b) all patent applications filed either from such patents, patent applications or provisional applications or from an application
claiming priority from either of these, including divisionals, continuations, continuations-in-part (other than with respect to new subject matter that would not otherwise be covered in this Agreement), provisionals, converted provisionals and
continued prosecution applications, (c) any and all patents that have issued or in the future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents and design patents and certificates of invention,
(d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the
foregoing patents or patent applications ((a), (b) and (c)), (e) any similar rights, including so-called pipeline protection or any importation, revalidation, confirmation or introduction patent or registration patent or patent of
additions to any of such foregoing patent applications and patents ((a), (b), (c) and (d)). 
 1.83
    “Salix/Alfa License Agreement” means that certain Amended and Restated License Agreement, dated 6 August 2012, between Alfa and Salix. 

1.84     “Salix/Alfa Supply Agreement” means that certain Supply Agreement, dated
24 June 1996, between Alfa and Salix, as amended. 
 1.85     “Third
Party” means any Person other than Lupin, Salix and their respective Affiliates. 
 1.86
    “Third Amendment Effective Date” means 15 May 2013. 
 2.2
    Article II of the Original Agreement is hereby amended to add at the end thereof a new Section 2.25, such new Section to read in its entirety as follows: 

2.25     Third Party Agreements. During the Term, Salix shall maintain in full force and
effect each of its agreements with Third Parties necessary to ensure that Lupin shall have the right to Manufacture (including process development insofar as it relates to the Manufacturing process) for Salix and supply to Salix Compound that is
Manufactured (including process 

  
 2 

 
development insofar as it relates to the Manufacturing process) pursuant to the Specifications as in effect from time to time. For the purposes of Section 7.2(b), a breach of this
Section 2.25 shall be deemed a material breach of this Agreement. 
 2.3     Article IV
of the Original Agreement is hereby amended to add at the end thereof a new Section 4.3, such new Section to read in its entirety as follows: 
 4.3     Additional Representations and Warranties of Salix. Salix hereby represents and warrants to Lupin as of the Third Amendment Effective Date as follows: 

(a)     The disclosure by Salix to Lupin hereunder of the Specifications, and such other information
(including Alfa Confidential Information) as may from time to time be disclosed by Salix to Lupin, in connection with the Manufacture (including process development insofar as it relates to the Manufacturing process) and supply of Compound by Lupin
to Salix pursuant hereto, and the use by Lupin of the Specifications and such Salix-supplied information for the purpose of Manufacturing (including process development insofar as it relates to the Manufacturing process) and supplying Compound to
Salix as contemplated hereby, will not infringe or misappropriate any Patent or other intellectual property rights of Alfa or, to Salix’s Knowledge, any other Third Party. 

(b)     There is no Patent or other intellectual property right of Alfa or, to Salix’s
Knowledge, any other Third Party that would be infringed or misappropriated by (i) Lupin’s Manufacture (including process development insofar as it relates to the Manufacturing process) and supply of the Compound to Salix as contemplated
hereby or (ii) Salix’s performance of its obligations hereunder. 
 2.4
    Article V of the Original Agreement is hereby amended to add at the end thereof a new Section 5.8, such new Section to read in its entirety as follows: 

5.8     Confidentiality, Use and Non-Disclosure Obligations. 

(a)     Notwithstanding the provisions of Sections 5.1, 5.2, 5.3, and 5.5, in respect
of Alfa Confidential Information the provisions of this Section 5.8, and not the provisions of Sections 5.1, 5.2, 5.3, and 5.5, shall apply. 

(b)     At all times during the longer of the term of the Salix/Alfa License
Agreement and the term of this 

  
 3 

 
Agreement and for a period of [*] ([*]) years after the longer of the two aforesaid periods, Lupin shall keep secret and confidential, and shall use all reasonable efforts to ensure that the same
is kept confidential by its Affiliates, all Confidential Information disclosed to it by Salix and identified by Salix in writing at the time of such disclosure as Alfa Confidential Information (“Alfa Confidential Information”) and
shall not use the same for any purpose other than effecting the Manufacture (including process development insofar as it relates to the Manufacturing process) and supply of Compound to Salix under this Agreement, in each case other than as otherwise
set forth in Section 5.8(d). Without limiting the foregoing, Lupin agrees that it shall take the same level of measures to protect the confidentiality of Alfa Confidential Information which it takes with respect to its own confidential and
proprietary information, but not less than reasonable care. 
 (c)     Notwithstanding the
obligations contained in Section 5.8(b), Alfa Confidential Information shall not include any information that: 
 (i)     shall be in the public domain prior to disclosure to Lupin, or shall enter the public domain after the Third Amendment Effective Date otherwise than by reason of the fault,
negligence or wrongful act of Lupin; 
 (ii)     Lupin can show was in its
possession free of any obligation of confidentiality prior to the date of receipt or was independently developed by employees of Lupin without reference to the information disclosed by Salix; or 

(iii)     is subsequently received by Lupin from a third party (not including Alfa)
who is not bound by any obligation of confidentiality with respect to said information; 
 Specific aspects or
details of Alfa Confidential Information shall not be deemed to be within the public domain or in the possession of Lupin merely because the Alfa Confidential Information is embraced by more general information in the public domain or in the
possession of Lupin. Further, any combination of Alfa Confidential Information shall not be considered in the public domain or in the possession of Lupin merely because individual elements of such Alfa Confidential Information are in the public
domain or in the possession of Lupin unless the 
  

	*	 Confidential treatment requested; certain information omitted and filed separately with the SEC

  
 4 

 
combination and its principles are in the public domain or in the possession of Lupin. 
 (d)     Lupin may disclose Alfa Confidential Information to the extent that such disclosure is: 

(i)     Made pursuant to a valid and effective subpoena or order issued by a court
of competent jurisdiction or other legal process or other supra-national, federal, national, regional, state, provincial or local governmental or regulatory body of competent jurisdiction or, if in the reasonable opinion of Lupin’s legal
counsel, such disclosure is otherwise required by law, provided that it shall (A) immediately notify Salix that it is subject to such legally required disclosure, (B) consult with Salix on the advisability of taking legally available steps
to resist or narrow such compelled disclosure, (C) reasonably assist Salix, at its request, in its efforts to obtain an appropriate protective order or other reliable assurance that confidential treatment shall be accorded to the Alfa
Confidential Information, to the extent such assistance is commercially reasonable, and (D) limit disclosure to the information that its legal counsel advises must be disclosed to comply with the legal requirement. 

(ii)     Made pursuant to Section 2.24. 

(e)     Lupin acknowledges and agrees that Salix has represented to Lupin that Alfa
Confidential Information constitutes unique and valuable trade secrets and that the unauthorized disclosure or use of Alfa Confidential Information would result in irreparable harm to Salix and Alfa for which monetary damages would be inadequate.
Accordingly, Lupin agree that in the event of any breach or threatened breach of this Section 5.8, Salix shall be entitled to obtain injunctive or other equitable relief from any court of competent jurisdiction in addition to all other remedies
available to it, and Lupin shall not claim as a defense thereto that Salix has an adequate remedy at law. In any such action for injunctive or equitable relief, Salix shall not be required to post a bond or other security. The Parties hereby
irrevocably consent to the jurisdiction of the courts of the State of New York and the United States District Court for the Southern District of New York, in either case sitting in the Borough of Manhattan in the City of New York, over any legal
action brought under this Section 5.8. 

  
 5 

 2.5     Clause (c) of Section 7.2 of the
Original Agreement is hereby deleted in its entirety and replaced with new clause (c), such new clause (c) to read in its entirety as follows: 
 (c)     any Third Party Claim made by any Person that (i) the disclosure by Salix of the Specifications and such information (including Alfa Confidential Information) as Salix may
from time to time disclose to Lupin hereunder and the use of the Specifications or any such Salix-supplied information by Lupin for purposes of Manufacturing (including process development insofar as it relates to the Manufacturing process) and
supplying Compound to Salix as contemplated hereby or (ii) the Manufacture (including process development insofar as it relates to the Manufacturing process) and supply of the Compound by Lupin to Salix as contemplated hereby in either case
((i) or (ii) infringes, misappropriates or otherwise violates the Patent, trademark or other intellectual property rights of such Person, 
 ARTICLE III.         MISCELLANEOUS 
 3.1     Representations and Warranties of Each Party. Each Party hereby represents and warrants to the other Party as of the Third Amendment Effective Date as follows:

 (a)     Such Party (i) is duly formed and in good standing under
the laws of the jurisdiction of its formation, (ii) has the power and authority and the legal right to enter into this Amendment and perform its obligations hereunder, and (iii) has taken all necessary action on its part required to
authorize the execution and delivery of this Amendment and the performance of its obligations hereunder. This Amendment has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding obligation of such Party
and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other similar laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability
of specific performance and general principles of equity, whether enforceability is considered in a proceeding at law or equity. 
 (b)     All necessary consents, approvals and authorizations of all regulatory and governmental authorities and other Persons required to be obtained by such Party in connection with
the execution and delivery of this Amendment and the performance of its obligations hereunder and under the Original Agreement as amended hereby have been obtained. 

  
 6 

 (c)     The execution and delivery of
this Amendment and the performance of such Party’s obligations hereunder and under the Original Agreement as amended hereby (i) do not and will not conflict with or violate any requirement of applicable law or any provision of the articles
of incorporation, bylaws, limited partnership agreement or other similar documents of such Party and (ii) do not and will not conflict with, violate, or breach, or constitute a default or require any consent under, any court or administrative
order or any contractual obligation by which such Party is bound, including, with respect to Salix, any of its agreements with Alfa, including the Salix/Alfa License Agreement and the Salix/Alfa Supply Agreement. 

(d)     Neither such Party nor any of its Affiliates has been debarred or is
subject to debarment pursuant to Section 306 of the FFDCA or listed on either Excluded List. 
 (e)     Neither such Party nor any of its Affiliates will use in any capacity, in connection with the services to be performed under the Original Agreement as amended hereby, any
Person who has been debarred pursuant to Section 306 of the FFDCA, or who is the subject of a conviction described in such section, or listed on either Excluded List. 

(f)     Each Party will inform the other Party in writing immediately if it or any
Person who is performing services under the Original Agreement as amended hereby is debarred or is the subject of a conviction described in Section 306 of the FFDCA or listed on either Excluded List, or if any action, suit, claim, investigation
or legal or administrative proceeding is pending or, to the best of such Party’s knowledge, is threatened, relating to the debarment or conviction under Section 306 of the FFDCA, or listing on either Excluded List, of such Party or any
Person performing services under the Original Agreement as amended hereby. 
 3.2
    Entire Agreement. 
 (a)     This Amendment sets forth and
constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto are superseded
hereby. Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth herein. 
 (b)     The Original Agreement, as amended pursuant to the terms of this Amendment, shall continue in full force and effect. 

3.3     Counterparts; Facsimile Execution. This Amendment may be executed in any number of
counterparts, each of which shall be deemed to be an original, and all of 

  
 7 

 
which, taken together, shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page of this Amendment by facsimile or other electronic transmission shall
be as effective as delivery of a manually executed original counterpart of such signature page. 
 3.4
    English Language. This Amendment shall be written and executed in, and all other communications under or in connection with this Amendment shall be in, the English language. Any translation into any other language
shall not be an official version thereof, and in the event of any conflict in interpretation between the English version and such translation, the English version shall control. 

[The remainder of this page has been intentionally left blank.] 

  
 8 

 IN WITNESS WHEREOF, the Parties hereto have executed this Amendment to be
effective as of the Third Amendment Effective Date. 
  

					
	 SALIX PHARMACEUTICALS, INC.
	 		 	 LUPIN LTD.

			
	 By: /s/ Rick
Scruggs                    
	 		 	 By: /s/ Nilesh
Gupta                          

			
	 Name: Rick Scruggs                    
	 		 	 Name: Nilesh
Gupta                          

			
	 Title: EVP of Business Development        
	 		 	 Title: Group
President                        

  
  
  

 
  

  
 [Signature
page to Third Amendment to Rifaximin Manufacturing and Supply Agreement]EX-10.2

 Exhibit 10.2 
 EIGHTH AMENDMENT 
 TO THE AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT

 EIGHTH AMENDMENT, dated as of July 31, 2013 (this “Amendment”), to the Amended and Restated Loan
and Security Agreement dated as of November 5, 2007 (as amended prior to the date hereof, the “Loan Agreement”), by and among (i) LSB INDUSTRIES, INC., a Delaware corporation (the “Parent”), Consolidated
Industries Corp., an Oklahoma corporation (“Consolidated Industries” and together with the Parent, each a “Guarantor” and collectively, the “Guarantors”), THERMACLIME, L.L.C., an Oklahoma limited
liability company (“ThermaClime”), and each of the Subsidiaries of ThermaClime identified on the signature pages thereof (such Subsidiaries, together with ThermaClime, each a “Borrower”, and collectively, the
“Borrowers”), (ii) the lenders identified on the signature pages thereof (each a “Lender” and collectively the “Lenders”), and (iii) WELLS FARGO CAPITAL FINANCE, INC., a California
corporation formerly known as Wells Fargo Foothill, Inc., as the arranger and administrative agent for the Lenders (the “Agent”). 
 WHEREAS, the Borrowers, the Guarantors, the Lenders, and the Agent desire to enter into this Amendment so as to amend the Loan Agreement as set forth herein subject to the terms and conditions hereof.

 NOW THEREFORE, in consideration of the premises and other good and valuable consideration, the parties hereto hereby agree as
follows: 
 1. Capitalized Terms. All capitalized terms used in this Amendment (including, without limitation, in the
recitals hereto) and not otherwise defined shall have their respective meanings set forth in the Loan Agreement. 
 2. New
Definitions. Section 1.1 of the Loan Agreement is hereby amended by adding the following defined terms in proper alphabetical order: 
 “”Covenant Condition” means, as of any date of determination, (i) no Default or Event of Default has occurred and is continuing and (ii) Excess Availability is equal to or
greater than the greater of (x) 20% of the Maximum Revolver Commitment or (y) $20,000,000.” 

“”Eighth Amendment” means that certain Eighth Amendment to the Amended and Restated Loan and
Security Agreement, dated as of July 31, 2013 among the Parent, Consolidated Industries, the Borrowers, the Lenders and the Agent.” 
 “”Eighth Amendment Effective Date” means the date that all of the conditions set forth in Section 16 of the Eighth Amendment shall be satisfied (or waived by the Agent in its
sole discretion).” 
 “”LSB Notes” means the general senior secured notes of Parent
maturing in 2019 in the aggregate principal amount of $400,000,000 to $450,000,000.” 

 “”Third Party Hedge Agreement” means any and all
transactions, agreements, or documents now existing or hereafter entered into between any Borrower or its Subsidiaries and any party other than a Bank Product Provider, which provide for an interest rate, credit, commodity or equity swap, cap,
floor, collar, forward foreign exchange transaction, currency swap, cross currency rate swap, currency option, or any combination of, or option with respect to, these or similar transactions, for the purpose of hedging that Borrower’s or its
Subsidiaries’ exposure to fluctuations in interest or exchange rates, loan, credit exchange, security or currency valuations or commodity prices.” 
 “”Third Party Hedge Obligations” means any and all obligations or liabilities, whether absolute or contingent, due or to become due, now existing or hereafter arising, of each
Borrower and its Subsidiaries arising under, owing pursuant to, or existing in respect of Third Party Hedge Agreements.” 

3. Maximum Revolver Amount. The definition of “Maximum Revolver Amount” in Section 1.1 of the Loan Agreement is
hereby amended and restated in its entirety to read as follows: 
 “”Maximum Revolver
Amount” means $100,000,000 minus the aggregate principal amount of the Term Loan then outstanding.” 
 4.
Permitted Investments. The definition of “Permitted Investments” in Section 1.1 of the Loan Agreement is hereby amended and restated in its entirety to read as follows: 

“”Permitted Investments” means (a) Investments in Cash Equivalents, (b) Investments in
negotiable instruments for collection, (c) advances made in connection with purchases of goods or services in the ordinary course of business, (d) Investments by any Borrower or Guarantor in any other Borrower or any Guarantor (other than
Parent), (e) guarantees by a Borrower or Guarantor of Indebtedness permitted under Section 7.1(e), (f) guarantees permitted under Section 7.6, (g) other Investments set forth on Schedule 7.13 hereto,
(h) Investments made by any Borrower or Guarantor (other than the Parent) in the Parent, provided that with respect to amounts in excess of $5,000,000 at any time outstanding, both immediately before and after giving effect to the making
of any such excess Investment, the Covenant Condition has been satisfied, (i) Investments in any newly created Subsidiary by means of purchase or other acquisition of the equity interests of such Subsidiary including by way of merger,
provided there is no investment of Collateral, (j) prior to ThermaClime’s distribution or dividend of the Special Distribution Amount to Parent pursuant to Section 7.11(a)(ii), the Borrowers may make Investments in an
aggregate amount not exceeding the Special Distribution Amount in the Special Permitted Investments, (k) Investments in joint ventures in an aggregate amount not exceeding $35,000,000, and (l) additional Investments in an aggregate amount
not exceeding $50,000,000 at any one time outstanding; provided, that both immediately before and after giving effect to the making of any Investments pursuant to clause (k) or (l), the Covenant Condition has been satisfied.”

 5. Permitted Liens. The definition of “Permitted Liens” in Section 1.1
of the Loan Agreement is hereby amended and restated in its entirety to read as follows: 

“”Permitted Liens” means (a) Liens held by Agent for the benefit of Agent and the Lenders,
(b) Liens for unpaid taxes that either (i) are not yet delinquent, or (ii) do not constitute an Event of Default hereunder and are the subject of Permitted Protests, (c) Liens set forth on Schedule P-1, (d) the
interests of lessors under operating leases, (e) purchase money Liens or the interests of lessors under Capital Leases to the extent that such Liens or interests secure Permitted Purchase Money Indebtedness and so long as such Lien attaches
only to the asset purchased or acquired and the proceeds thereof, (f) Liens arising by operation of law in favor of warehousemen, landlords, carriers, mechanics, materialmen, laborers, or suppliers, incurred in the ordinary course of
Borrowers’ business and not in connection with the borrowing of money, and which Liens either (i) are for sums not yet delinquent, or (ii) are the subject of Permitted Protests, (g) Liens arising from deposits made in connection
with obtaining worker’s compensation or other unemployment insurance, social security and other similar laws (h) Liens or deposits to secure performance of bids, tenders, or leases incurred in the ordinary course of Borrowers’
business and not in connection with the borrowing of money, (i) Liens granted as security for surety, payment, performance or appeal bonds in connection with obtaining such bonds in the ordinary course of Borrowers’ business,
(j) Liens resulting from any judgment or award that is not an Event of Default hereunder, (k) with respect to any Real Property, easements, exceptions, reservations, encroachments, restrictions, rights of way, zoning restrictions and other
similar title policy exceptions or encumbrances that do not materially interfere with or impair the use or operation thereof by Borrowers; (l) Liens on the BofA Collateral in favor of BofA (as collateral agent) on the Restatement Effective Date
securing the repayment of the BofA Loans and all other obligations under the BofA Loan Agreement; (m) Liens of the Orica Account Purchaser on the Specified Orica Accounts sold by a Borrower to the Orica Account Purchaser in accordance with
Section 7.4(c) hereof; (n) Liens in favor of BofA on the Specified BofA Accounts, which Specified BofA Accounts shall only contain proceeds of insurance in connection with the Specified Casualty; (o) Liens in favor of Bank of America,
N.A. and Merrill, Lynch, Pierce, Fenner & Smith Incorporated upon deposits of cash in the Specified BofA Accounts to the extent incurred in connection with the maintenance of such deposit accounts in the ordinary course of business;
(p) Liens arising in connection with Third Party Hedging Obligations; (q) Liens securing the LSB Notes so long as (i) to the extent any such Liens are on assets not currently constituting Collateral, the Agent is granted a second
priority Lien on such assets and (ii) such Liens are subject to an intercreditor agreement in form and substance satisfactory to the Agent, and (r) other Liens securing obligations or Indebtedness not in excess of $50,000,000 in the
aggregate at any one time outstanding.” 
 6. Permitted Purchase Money Indebtedness. The definition of
“Permitted Purchase Money Indebtedness” in Section 1.1 of the Loan Agreement is hereby amended and restated in its entirety to read as follows: 
 ““Permitted Purchase Money Indebtedness” means, as of any date of determination, Purchase Money Indebtedness not to exceed the greater of (x) $35,000,000 and (y) 5.0% of the total
consolidated assets of the Borrowers and their Subsidiaries as reflected on their balance sheet in accordance with GAAP.” 

 7. Section 2.1(a). Section 2.1(a) of the Loan Agreement is hereby amended
and restated in its entirety to read as follows: 
 “(a) Subject to the terms and conditions of this
Agreement, and during the term of this Agreement, each Lender with a Revolver Commitment agrees (severally, not jointly or jointly and severally) to make advances (“Advances”) to Borrowers in an amount at any one time outstanding
not to exceed such Lender’s Pro Rata Share of an amount equal to the lesser of (i) the Maximum Revolver Amount less the Letter of Credit Usage or (ii) the Borrowing Base less the Letter of Credit Usage. For purposes of this Agreement,
“Borrowing Base,” as of any date of determination, shall mean the result of the following for all Borrowers: 
 (A) the lesser of 
 (1) 85% of the amount of Eligible Accounts of
such Borrowers, less the amount, if any, of the sum of the Dilution Reserve, and 
 (2) an amount equal to such
Borrowers’ Collections with respect to Accounts for the immediately preceding 75 day period, plus 
 (B) the
lowest of 
 (1) $60,000,000, and 

(2) the sum of 
 (x) the lesser of (i) 70% of the value of such Borrowers’ Eligible Inventory, and (ii) 85% of the Net Orderly Liquidation Value of such Borrowers’ Eligible Inventory, plus 

(y) the lesser of (i) 60% (or, in the case of Climate Control Raw Inventory, 65%) of the value of such
Borrowers’ Eligible Raw Inventory, and (ii) 85% of the Net Orderly Liquidation Value of such Borrowers’ Eligible Raw Inventory, minus 
 (C) (z) the sum of (1) the Bank Products Reserve, and (2) the aggregate amount of reserves, if any, established by Agent under Section 2.1(b).” 

8. Section 3.4. Section 3.4 of the Loan Agreement is hereby amended and restated in its entirety to read as follows:

 “3.4 Term. This Agreement shall become effective upon the
execution and delivery hereof by the Borrowers, the Agent, and the Lenders and shall continue in full force and effect for a term ending on April 13, 2018 (the “Maturity Date”). The foregoing notwithstanding, the Lender Group,
upon the election of the Required Lenders, shall have the right to terminate its obligations under this Agreement immediately and without notice upon the occurrence and during the continuation of an Event of Default.” 

9. Section 7.1. Section 7.1(h) of the Loan Agreement is hereby amended and restated in its entirety to read as follows:

 “(h) other Indebtedness owing by any Borrower or any Subsidiary of a Borrower to any Subsidiary of Parent
that is not also a Subsidiary of ThermaClime;” 
 Furthermore, Section 7.1(i) of the Loan Agreement is hereby amended
and restated in its entirety to read as follows: 
 “(i) other Indebtedness in an aggregate principal amount
not to exceed $50,000,000 outstanding at any time;” 
 Furthermore, Section 7.1 of the Loan Agreement is hereby
amended by (i) deleting the “and” from the end of clause (k) thereto, (ii) deleting the period from the end of clause (l) thereto and substituting “;” therefor, and (iii) inserting a new clause
(m) immediately following clause (l), to read as follows: 
 “(m) Indebtedness of the Borrowers and
their Subsidiaries in respect of guarantees of the LSB Notes; and” 
 Furthermore, Section 7.1 of the Loan Agreement
is hereby amended by inserting a new clause (n) immediately following clause (m), to read as follows: 
 “(n)
Indebtedness in respect of Third Party Hedge Obligations, so long as both immediately before and after giving effect to the incurrence of any such Indebtedness, the Covenant Condition is satisfied; provided, however, that the foregoing
Covenant Condition shall not apply to the Hedge Obligations entered into with a Bank Product Provider.” 
 10.
Section 7.6. Section 7.6 of the Loan Agreement is hereby amended and restated in its entirety to read as follows: 
 “7.6 Guarantee. Guarantee or otherwise become in any way liable with respect to the obligations of any third Person except (i) by endorsement of instruments or items of payment for
deposit to the account of Borrowers or which are transmitted or turned over to Agent, (ii) for guarantees of the LSB Notes, (iii) for guarantees of Indebtedness permitted under Section 7.1 and guarantees set forth on Schedule 5.20
and (iv) for guarantees of performance, surety or appeal bonds of any Borrower or Guarantor (other than the Parent).” 

 11. Section 7.8(a). Section 7.8(a) of the Loan Agreement is hereby amended
and restated in its entirety to read as follows: 
 “(a) Except in connection with a refinancing permitted
by Section 7.1(d), prepay, redeem, defease, purchase, or otherwise acquire any Indebtedness of any Borrower or any Guarantor, other than the Obligations in accordance with this Agreement and as otherwise permitted in
Section 7.8(b) and Section 7.4(b); provided, that, ThermaClime may prepay the Indebtedness set forth on Schedule I to the Third Amendment, in amounts not to exceed the principal amounts set forth in such schedule plus
accrued interest, so long as (i) no Default or Event of Default has occurred and is continuing or would result therefrom, (ii) EBITDA for the fiscal quarter immediately preceding the date of such repurchase is not less than $5,000,000 and
(iii) after giving effect to such prepayment, Excess Availability is not less than $15,000,000; provided, further, that Borrowers may prepay the BofA Loans from (1)(x) cash on hand or (y) the proceeds of Advances so long
as, after giving effect to any such prepayment, Excess Availability is equal to or greater than the greater of (A) $10,000,000 and (B) an amount equal to 20% of the Total Commitment at the time of such prepayment or (2) proceeds from
the LSB Notes;” 
 12. Section 7.11. Section 7.11(e) of the Loan Agreement is hereby amended and restated
in its entirety to read as follows: 
 “(e) each Borrower and each of its Subsidiaries may make other
distributions and pay dividends to Consolidated Industries or to Parent or to any Subsidiary of Consolidated Industries that is not also a Subsidiary of ThermaClime, provided that with respect to amounts in excess of $500,000 during each fiscal
year, both immediately before and after giving effect to any such excess payments, the Covenant Condition has been satisfied;” 
 Furthermore, Section 7.11 of the Loan Agreement is hereby amended by (i) deleting the period from the end of clause (f) thereto and substituting “; and” therefor, and
(ii) inserting new clause (g) immediately following clause (f), to read as follows: 
 “(g) so
long as no Default or Event of Default has occurred and is continuing or would result therefrom, (i) ThermaClime may make distributions and pay dividends to Consolidated Industries or to Parent, in amounts necessary to permit Parent to make
required payments of principal and payments of scheduled interest under the LSB Notes (as in effect on the date hereof), in each case not more than 5 Business Days prior to the date such payments are due and not in excess of the actual amounts
due.” 
 13. Section 7.20(a)(iii). Section 7.20(a)(iii) of the Loan Agreement is hereby amended and
restated in its entirety to read as follows: 
 “(iii) Fixed Charge Coverage Ratio. At any time Excess
Availability is less than or equal to 12.5% of the Total Commitment (the “FCCR Trigger Date”), a Fixed Charge Coverage Ratio of not less than 1.10:1.00, measured monthly commencing on the FCCR Trigger Date with the most recently
ended month, on a trailing twelve month basis.” 

 14. Section 8.9. Section 8.9 of the Loan Agreement is hereby amended and
restated in its entirety to read as follows: 
 “8.9 If there is a default in any material agreement
(including, without limitation, the LSB Notes) to which any Borrower, any Guarantor (other than the Parent, Consolidated Industries and Cherokee) or any of its Subsidiaries is a party and such default (a)(i) occurs at the final maturity of the
obligations thereunder, or (ii) results in a right by the other party thereto, irrespective of whether exercised, to accelerate the maturity of the applicable Borrower’s, Guarantor’s or its Subsidiaries’ obligations thereunder,
to terminate such agreement, or to refuse to renew such agreement pursuant to an automatic renewal right therein, and (b) involves Indebtedness or an obligation for the payment of money in an aggregate amount in excess of $1,000,000;”

 15. Schedule C-1. Schedule C-1 of the Loan Agreement is hereby amended and restated in its entirety to read as follows:

 Commitments 
  

									
	 Lender
	  	Revolver
Commitment	 	  	Total
Commitment	 
	 Wells Fargo Foothill, Inc.
	  	$	100,000,000	  	  	$	100,000,000	  
	 All Lenders
	  	$	100,000,000	  	  	$	100,000,000	  

 16. Conditions Precedent. The effectiveness of this Amendment is subject to the fulfillment, in a
manner satisfactory to the Agent, of each of the following conditions precedent (the first date upon which all such conditions shall have been satisfied being herein called the “Eighth Amendment Effective Date”): 

(a) Representations and Warranties; No Event of Default. The representations and warranties contained herein, in
Section 5 of the Loan Agreement and in each other Loan Document and certificate or other writing delivered to the Agent or any Lender pursuant hereto on or prior to the Eighth Amendment Effective Date (as updated prior to the date hereof in
accordance with the Loan Agreement) shall be correct in all material respects on and as of the Eighth Amendment Effective Date as though made on and as of such date, except to the extent that such representations and warranties (or any schedules
related thereto) expressly relate solely to an earlier date (in which case such representations and warranties shall be true and correct in all material respects on and as of such date); and after giving effect to the amendments, consents and
waivers set forth herein, no Default or Event of Default shall have occurred and be continuing on the Eighth Amendment Effective Date or would result from this Amendment becoming effective in accordance with its terms. 

 (b) Payment of Amendment Fee. The Borrowers shall have paid to the Agent an amendment fee
equal to $75,000. The Borrowers hereby authorize the Agent to draw this amendment fee against the Loan Account on the Eighth Amendment Effective Date. 
 (c) Delivery of Documents. The Agent shall have received on or before the Eighth Amendment Effective Date the following, each in form and substance satisfactory to the Agent and, unless indicated
otherwise, dated the Eighth Amendment Effective Date: 
 (i) counterparts of this Amendment duly executed by the Borrowers, the
Agent and the Lenders; 
 (ii) a certificate from the Secretary or Assistant Secretary of each Borrower, Consolidated Industries
and Parent attesting to the resolutions of such Borrower’s or Guarantor’s Board of Directors or Board of Managers, as applicable, or committee thereof authorizing its execution, delivery, and performance of this Amendment and the other
Loan Documents (as amended by this Amendment) to which such Borrower or Guarantor is a party and authorizing specific officers of such Borrower to execute the same; 
 (iii) copies of each Borrower’s, Consolidated Industries’ and Parent’s Governing Documents, as amended, modified, or supplemented to the Eighth Amendment Effective Date, certified by the
Secretary or Assistant Secretary of such Borrower or such Guarantor; and 
 (iv) a certificate of status with respect to each
Borrower, Consolidated Industries and Parent, dated no earlier than 60 days prior to the Eighth Amendment Effective Date, such certificate to be issued by the appropriate officer of the jurisdiction of organization of such Borrower or such
Guarantor, which certificate shall indicate that such Borrower or such Guarantor is in good standing in such jurisdiction. 

(d) Effectiveness of the LSB Notes. (i) The LSB Notes shall have been issued and the proceeds therefrom shall have been received by
the Parent, and (ii) the proceeds from the LSB Notes shall be used, in part, to repay in full the BofA Loans and all obligations related thereto. 
 17. Representations and Warranties. Each Borrower, and only with respect to parts (b) and (c) below, Parent and Consolidated Industries, hereby represents and warrants to the Agent and
the Lenders as follows: 
 (a) Representations and Warranties; No Event of Default. The representations and warranties herein,
in Section 5 of the Loan Agreement (as updated prior to the date hereof in accordance with the Loan Agreement), and in each other Loan Document and certificate or other writing delivered to the Agent or any Lender pursuant hereto on or prior to
the Eighth Amendment Effective Date are correct in all material respects on and as of the Eighth Amendment Effective Date as though made on and as of such date, except to the extent that such representations and warranties (or any schedules related
thereto) expressly relate solely to an earlier date (in which case such representations and warranties are true and correct in all material respects on and as of such date); and after giving effect to the amendments, consents and waivers set forth
herein, no Default or Event of Default has occurred and is continuing on the Eighth Amendment Effective Date or would result from this Amendment becoming effective in accordance with its terms; 

 (b) Organization, Good Standing, Etc. Parent, Consolidated Industries and each Borrower
(i) is a corporation duly organized, validly existing and in good standing under the laws of the state of its organization, (ii) has all requisite power and authority to execute, deliver and perform this Amendment and the other Loan
Documents to which it is a party being executed in connection with this Amendment, and to perform its respective obligations under the Loan Agreement, as amended hereby, and (iii) is duly qualified to do business and is in good standing in each
jurisdiction in which the character of the properties owned or leased by it or in which the transaction of its business makes such qualification necessary except where the failure to be so qualified reasonably could not be expected to have a
Material Adverse Change. 
 (c) Authorization, Etc. The execution, delivery and performance by each Borrower, Parent and
Consolidated Industries of this Amendment, and the performance by each Borrower, Parent and Consolidated Industries of the Loan Agreement and the other Loan Documents to which it is a party, each as amended hereby, (i) have been duly authorized
by all necessary action on the part of such Borrower, Parent or Consolidated Industries, (ii) do not and will not contravene such Borrower’s, Parent’s or Consolidated Industries’ charter or by-laws, any applicable law or any
material contractual restriction binding on it or any of its properties, (iii) do not and will not result in or require the creation of any Lien (other than pursuant to any Loan Document) upon or with respect to any of its properties, and
(iv) do not and will not result in any suspension, revocation, impairment, forfeiture or nonrenewal of any permit, license, authorization or approval applicable to its operations or any of its properties. 

18. Miscellaneous. 
 (a) Continued Effectiveness of the Loan Agreement. Except as otherwise expressly provided herein, the Loan Agreement and the other Loan Documents are, and shall continue to be, in full force and effect
and are hereby ratified and confirmed in all respects, except that on and after the Eighth Amendment Effective Date (i) all references in the Loan Agreement to “this Agreement”, “hereto”, “hereof”,
“hereunder” or words of like import referring to the Loan Agreement shall mean the Loan Agreement as amended by this Amendment, and (ii) all references in the other Loan Documents to which any Borrower is a party to the “Loan
Agreement”, “thereto”, “thereof”, “thereunder” or words of like import referring to the Loan Agreement shall mean the Loan Agreement as amended by this Amendment. Except as expressly provided herein, the execution,
delivery and effectiveness of this Amendment shall not operate as an amendment, modification or waiver of any right, power or remedy of the Lender under the Loan Agreement or any other Loan Document, nor constitute an amendment of any provision of
the Loan Agreement or any other Loan Document. 

 (b) Counterparts. This Amendment may be executed in any number of counterparts and by
different parties hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement. 

(c) Headings. Section headings herein are included for convenience of reference only and shall not constitute a part of this Amendment
for any other purpose. 
 (d) Governing Law. This Amendment shall be governed by, and construed in accordance with, the law of
the State of New York. 
 (e) Costs and Expenses. The Borrowers jointly and severally agree to pay on demand all reasonable
fees, costs and expenses of the Agent and each Lender in connection with the preparation, execution and delivery of this Amendment and the other related agreements, instruments and documents. 

(f) Amendment as Loan Document. Each Borrower hereby acknowledges and agrees that this Amendment constitutes a “Loan Document”
under the Loan Agreement. Accordingly, it shall be an Event of Default under the Loan Agreement (i) if any representation or warranty made by a Borrower under or in connection with this Amendment shall have been untrue, false or misleading in
any material respect when made or (ii) if Borrowers fail to perform, keep, or observe any term, provision, condition, covenant, or agreement contained in this Amendment. 
 (g) General Release. Each Borrower and Guarantor hereby acknowledges and agrees that no Borrower or Guarantor has, as of the date of this Amendment, any defense, counterclaim, offset, cross-complaint, claim or demand of any kind or nature whatsoever that can be asserted to reduce or eliminate all or any part of its liability to repay the obligations or to seek affirmative relief or damages of any
kind or nature from the Agent, any member of the Lender Group or any other Lender-Related Persons. Each Borrower and Guarantor hereby voluntarily and knowingly releases and forever discharges the Agent, each member of the Lender Group, the other
Lender-Related Persons and each of their respective predecessors, agents, employees, attorneys, successors and assigns (collectively, the “Released Parties”) from all possible claims, demands, actions, causes of action, damages,
costs, expenses and liabilities whatsoever, whether known or unknown, anticipated or unanticipated, suspected or unsuspected, fixed, contingent or conditional, or at law or in equity, in any case originating in whole or in part on or before the date
this Amendment is executed that any Borrower or Guarantor may now or hereafter have against the Released Parties, if any, irrespective of whether any such claims arise out of contract, tort, violation of law or regulations, or otherwise, and that
arise from any Loans, the exercise of any rights and remedies under the Loan Agreement or other Loan Documents, and/or negotiation for and execution of this Amendment, including, without limitation, any contracting for, charging, taking, reserving,
collecting or receiving interest in excess of the highest lawful rate applicable. 

 (h) Waiver of Jury Trial. EACH BORROWER, THE AGENT AND THE LENDERS HEREBY IRREVOCABLY WAIVE
THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AMENDMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON
LAW OR STATUTORY CLAIMS. 
 [THE REMAINDER OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK] 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed and
delivered as of the date first above written. 
  

			
	 Parent:

	
	 LSB INDUSTRIES, INC.,
 a Delaware corporation

		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President
	
	Consolidated Industries:
	
	 CONSOLIDATED INDUSTRIES CORP.,
 an Oklahoma corporation

		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President
	
	Borrowers:
	
	 THERMACLIME, L.L.C.,
 an Oklahoma limited liability company

		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President
	
	 CHEROKEE NITROGEN COMPANY,
 an Oklahoma corporation

		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President

 
			
	CLIMATE MASTER, INC.,
	a Delaware corporation
		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President
	
	 CLIMATECRAFT, INC.,
 an Oklahoma corporation

		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President
	
	 CLIMACOOL, CORP.,
 an Oklahoma corporation

		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President
	
	 INTERNATIONAL ENVIRONMENTAL CORPORATION,
 an Oklahoma corporation

		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President
	
	 THERMACLIME TECHNOLOGIES, INC.,
 an Oklahoma corporation

		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President

 
			
	KOAX CORP., an Oklahoma corporation
		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President
	
	 LSB CHEMICAL CORP.,
 an Oklahoma corporation

		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President
	
	XPEDIAIR, INC., an Oklahoma corporation.
		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President
	
	 EL DORADO CHEMICAL COMPANY,
 an Oklahoma corporation

		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President
	
	CHEMEX I CORP., an Oklahoma corporation
		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President

 : 

 
			
	 TRISON CONSTRUCTION, INC.,
 an Oklahoma corporation

		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President
	
	 EDC AG PRODUCTS COMPANY L.L.C.,
 an Oklahoma limited liability company

		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President
	
	 EL DORADO AMMONIA L.L.C.,
 an Oklahoma limited liability company

		
	By:	 	/s/ Tony M. Shelby
		 	Name: Tony M. Shelby
		 	Title: Executive Vice President

 
			
	Agent and Lender:
	
	 WELLS FARGO CAPITAL FINANCE, INC.,
 a California corporation, as Agent and Lender

		
	By:	 	/s/ Matt Mouledous
		 	Name: Matt Mouledous
		 	Title: Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]